### Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients

See how a QSP model guided efficacy-proximal FIH dosing for ISB 2001 in the TRIgnite-1 study.

### Review: application and opportunities for machine learning and artificial intelligence in preclinical immunogenicity risk assessment

### Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

### Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models

### Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

### Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

### Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

### Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome

### Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

### Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics